M. Lazenby

Synthesis and endosomolytic properties of poly(amidoamine) block copolymers.

R. Duncan, P. Ferruti, Nathalie Lavignac, 2004, Macromolecular bioscience.

The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

M. Lazenby, C. Pepper, A. Burnett, 2011, Leukemia.

Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics.

R. Duncan, P. Ferruti, Nathalie Lavignac, 2005, International journal of pharmaceutics.

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

R. Hills, M. Lazenby, A. Burnett, 2014, Leukemia.

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine

R. Hills, M. Lazenby, J. Zabkiewicz, 2015, Leukemia research.

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

R. Hills, D. Linch, M. Lazenby, 2008 .

Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia

R. Hills, M. Lazenby, A. Burnett, 2020, British journal of haematology.

Characterisation of extracellular vesicles from the microenvironment in high risk acute myeloid leukaemia

M. Lazenby, 2019 .

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

E. Estey, J. Radich, S. Meshinchi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

R. Hills, N. Russell, L. Kjeldsen, 2013 .

The HSP90 inhibitor NVP‐AUY922‐AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells

M. Lazenby, A. Burnett, S. Knapper, 2013, British journal of haematology.